CryoValve SG Pulmonary Human Heart Valve. The valve is cryopreserved in a tissue culture medium ...
FDA Device Recall #Z-0652-2021 — Class II — November 10, 2020
Recall Summary
| Recall Number | Z-0652-2021 |
| Classification | Class II — Moderate risk |
| Date Initiated | November 10, 2020 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | CryoLife, Inc. |
| Location | Kennesaw, GA |
| Product Type | Devices |
| Quantity | 3 units |
Product Description
CryoValve SG Pulmonary Human Heart Valve. The valve is cryopreserved in a tissue culture medium containing cryoprotectants within the innermost pouch of a three-pouch packaging system. The packaging system not only withstands ultracold temperatures, but also allows for aseptic introduction of the valve into the operating environment. Supercooling by liquid nitrogen boost is begun prior to crystallization to minimize ice crystal damage to the valve matrix. Finally, the valve is transferred to a liquid nitrogen freezer for long-term storage at or below 135¿C. CryoValve SG is distributed in two anatomic configurations: pulmonary valve and conduit, and pulmonary valve.
Reason for Recall
On November 10, 2020, it was discovered that there are post- processing microbial culture test failures for other allografts, processed using a TRIS saline solution lot that was also used in processing allografts subjected to the recall.
Distribution Pattern
Distributed nationwide to GA, AZ, TX, MO, and OK.
Lot / Code Information
Model/Catalog Number: SGPV00 Serial Numbers: 11685214, 11685554, and 11682491 UDI: 00877234000447
Other Recalls from CryoLife, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-0384-2022 | Class II | BioGlue Surgical Adhesive, Model BG3510-5-G | Oct 7, 2021 |
| Z-0653-2021 | Class II | CryoPatch SG Pulmonary Human Cardiac Patch. Th... | Nov 10, 2020 |
| Z-1073-2019 | Class II | On-X Aortic Heart Valve with Anatomic Sewing Ri... | Jan 17, 2019 |
| Z-0121-2019 | Class II | CryoPatch SG Pulmonary Hemi-Artery, 1 graft | Sep 6, 2018 |
| Z-2556-2018 | Class II | BioGlue Spreader Tip, 12mm, Sterile, RX Only. ... | Jun 4, 2018 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.